COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

All patients tolerated COMP360 psilocybin therapy well.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

πŸ“° Weekly newsletter about the psychedelic research

βœ”οΈ Unlimited access to our database and original articles

πŸ–ŠοΈ Add (private) notes and comments to each page

Make an account
Category Press Release
Country United Kingdom

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.

0 Comments
Inline Feedbacks
View all comments